The Digest

Pharma news roundup and Larvol updates

Contact Us
Month: January 2020

Weekly Top News – IBD– January 6, 2020

January 6, 2020

etrasimod (APD334) / Arena
Etrasimod clinical trial estimate: Data from P2b/3 CULTIVATE trial (NCT04173273) for Crohn’s disease in H2 2021 (SVB Leerink) – Jan 6, 2020 – A subscription to Thomson ONE is required to gain full access to report 68502627; Page no: 72; REPORT TITLE: “2020 outlook for investing in healthcare”; AUTHOR: Sullivan, John, et al; DATE: 12/16/2019

 

etrasimod (APD334) / Arena
Etrasimod clinical trial estimate: Data from P3 ELEVATE UC 52 trial (NCT03945188) for ulcerative colitis at year end 2021 (SVB Leerink) – Jan 6, 2020 – Etrasimod clinical trial estimate: Data from P3 ELEVATE UC 52 trial (NCT03945188) for ulcerative colitis at year end 2021

 

Myoconda (clarithromycin/clofazimine/rifabutin) / RedHill
MAPUS: Efficacy and Safety of Anti-MAP Therapy in Adult Crohn’s Disease (clinicaltrials.gov) – Jan 2, 2020 – P3; N=331; Completed; Sponsor: RedHill Biopharma Limited; Active, not recruiting –> Completed; Trial completion date: Apr 2019 –> Aug 2019

 

Stelara (ustekinumab) / J&J
Stelara patent expiry: January 2024 in EU (Barclays) – Jan 2, 2020 – A subscription to Thomson ONE is required to gain full access to report 68519497; Page no: 8; REPORT TITLE: “Johnson & Johnson: Last minute gift idea? JNJ; Upgrade to overweight”; AUTHOR: Stewart, Kristen, et al; DATE: 12/19/2019

 

Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA
Xifaxan patent protection: Until 2031 for soluble solid dispersion tablets (Guggenheim) – Dec 30, 2019 – A subscription to Thomson ONE is required to gain full access to report 68502576; Page no: 4; REPORT TITLE: “Bausch Health Companies Ltd- BHC (Buy) – Hepatic encephalopathy (HE) deep dive ahead of phase 2 data”; AUTHOR: Research Department; DATE: 12/16/2019

 

Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Simponi patent expiry: April 2025 in EU and February 2024 in US (Barclays) – Jan 2, 2020 – A subscription to Thomson ONE is required to gain full access to report 68519497; Page no: 8; REPORT TITLE: “Johnson & Johnson: Last minute gift idea? JNJ; Upgrade to overweight”; AUTHOR: Stewart, Kristen, et al; DATE: 12/19/2019

 

filgotinib (GLPG0634) / Gilead
Filgotinib WW sales projection: $6.7B in 2030 (Morgan Stanley) – Jan 3, 2020 – A subscription to Thomson ONE is required to gain full access to report 68506973; Page no: 207; REPORT TITLE: “Biotechnology: 2020 outlook: Still a stockpickers’ world, but macro pressures receding”; AUTHOR: Harrison, Matthew, et al; DATE: 12/17/2019

 

Humira (adalimumab) / Eisai, AbbVie
Pfizer, AbbVie and Gilead among drugmakers boosting prices to start 2020 (BioPharma Dive) – Jan 2, 2020 – “Some of the largest pharmaceutical and biotech companies started 2020 by increasing U.S. list prices for a range of top-selling medications, despite intense political scrutiny on the industry and its pricing practices…AbbVie raised the list price of Humira (adalimumab), the world’s best-selling drug, by 7.4%, according to Raymond.”

 

Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA
Xifaxan patent protection: Until 2027 (Cowen & Co) – Dec 30, 2019 – A subscription to Thomson ONE is required to gain full access to report 68468883; Page no: 1; REPORT TITLE: “Bausch Health Companies Ltd- Best ideas for 2020: Continued execution should generate significant value”; AUTHOR: Cacciatore, Ken,et al; DATE: 12/09/2019

 

Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA
Xifaxan sales projection: $2.3B by 2028 (Guggenheim) – Dec 30, 2019 – A subscription to Thomson ONE is required to gain full access to report 68502576; Page no: 2; REPORT TITLE: “Bausch Health Companies Ltd- BHC (Buy) – Hepatic encephalopathy (HE) deep dive ahead of phase 2 data”; AUTHOR: Research Department; DATE: 12/16/2019

Read More …

Weekly Top News – Psoriasis– January 6, 2020

January 6, 2020

Stelara (ustekinumab) / J&J
Stelara patent expiry: January 2024 in EU (Barclays) – Jan 2, 2020 – A subscription to Thomson ONE is required to gain full access to report 68519497; Page no: 8; REPORT TITLE: “Johnson & Johnson: Last minute gift idea? JNJ; Upgrade to overweight”; AUTHOR: Stewart, Kristen, et al; DATE: 12/19/2019

 

AVT02 (adalimumab biosimilar) / Alvotech, Cipla; Humira (adalimumab) / Eisai, AbbVie
Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis (clinicaltrials.gov) – Jan 3, 2020 – P3; N=413; Active, not recruiting; Sponsor: Alvotech Swiss AG; Recruiting –> Active, not recruiting; Initiation date: Feb 2019 –> Dec 2019

Read More …
Next Entries »